Nav: Home

Switching to aspirin/clopidogrel following 1 month of new P2Y12 inhibitor/aspirin post-ACS

May 16, 2017

Reporting results from the first randomised study to compare these two DAPT regimens, lead author Thomas Cuisset, Interventional Cardiologist at CHU Timone, Marseille, France, predicted that they would change clinical practice.

Newer P2Y12 inhibitors such as prasugrel or ticagrelor in combination with aspirin have become the first-line initial DAPT following an ACS and this has been extended, by default, to one year. Previous studies have shown that this DAPT regimen achieves a greater reduction in ischaemia in the first 30 days but this is followed by a significant increase in bleeding risk during longer-term maintenance treatment.

The TOPIC (Timing of Platelet Inhibition after acute Coronary syndrome) study investigated whether giving one-month initial treatment with a newer P2Y12 inhibitor plus aspirin after a PCI for ACS and then switching to maintenance DAPT with aspirin plus clopidogrel could reduce bleeding risk without any ischaemic adverse effects.

TOPIC recruited 646 ACS patients undergoing PCI who were treated with a new P2Y12 inhibitor plus aspirin for one month before being randomised to continue with this dual antiplatelet therapy or switch to aspirin (75 mg) plus clopidogrel (75 mg).

The combined primary endpoint of death, urgent revascularisation, stroke and bleeding (with a Bleeding Academic Research Consortium [BARC] classification ≥ 2) was 52% lower at one year in patients switched to aspirin plus clopidogrel compared to those continuing on a new P2Y12 inhibitor plus aspirin (13.4% with switched DAPT vs. 26.3% with unchanged DAPT, hazard ratio [HR] 0.48, 95% confidence interval [CI]: 0.34-0.68, p<0.01).

There was no difference in ischaemic events between the two dual antiplatelet regimens (9.3% of patients on switched DAPT had an ischaemic event vs. 11.5% of patients on unchanged DAPT, HR 0.80, 95% CI: 0.50-1.29, p=0.36). However, the rate of bleeding (BARC ≥2) was 70% lower in patients who switched DAPT compared to those on unchanged DAPT (4.0% vs. 14.9% at one year, HR 0.30, 95% CI: 0.18-0.50, p<0.01).

"In patients without adverse events at one month after undergoing PCI with stenting for ACS, switched dual antiplatelet therapy is superior to unchanged DAPT in reducing bleeding events without increasing the risk of ischaemic events," said Cuisset.

"This strategy could be proposed in ACS patients," he suggested, adding, "We think that this trial could change practice." However, he noted that many physicians already use switched DAPT so the likely impact would be to increase the number of patients treated this way. He cautioned, "The remaining question will be to assess which patients can be switched at one month and which patients should continue with 'stronger DAPT'."

Commenting on the results, Stefan James, Professor of Cardiology at Uppsala University, Sweden, said, "The trial results suggest, as expected, that switching therapy reduces minor bleeding events." However, he cautioned that the trial was "underpowered to evaluate clinically important ischaemic events that, unexpectedly, were fewer with the switching strategy," and was limited by its single-centre, open-label design. He concluded, "This precludes any meaningful interpretation for clinical practice. Several major pivotal trials have shown a continuous benefit of longer-term therapy with potent and predictable platelet inhibition. Thus the TOPIC study should not change clinical practice."
Contact information

Contact: Thomas Cuisset, CHU Timone, Marseille, France

Corresponding session

EuroPCR 2017 session: Tuesday 16 May 11:30-12:50: Hot Line/Late-breaking trials, Coronary Interventions, Interventions for Valvular Disease, Left main and multivessel disease, NSTEMI, STEMI, Stents and scaffolds, TAVI; Main arena

Help for journalists to cover EuroPCR 2017

For any press-related inquiries, please contact:

EuroPCR Press Coordinator, Isabelle Uzielli

Register and attend EuroPCR 2017 as a journalist

Press registration for EuroPCR is open to accredited journalists, free of charge. Journalists must hold a valid press card and/or provide a letter of assignment from a recognised publication. To register as press go to

EuroPCR press releases

EuroPCR press releases can be found at

Attend press briefings

For the press briefing schedule check

EuroPCR abstracts

Abstracts are available online at

Notes to Editors

What is EuroPCR?

EuroPCR, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), a registered branch of the European Society of Cardiology, is the world-leading course in interventional cardiovascular medicine. PCR has established a distinctive format for educational activities in the field of cardiovascular interventions. Beyond its flagship course in Paris that gathers more than 11,500 participants every year, PCR organises annual courses in Singapore, London UK, Dubai EAU, Johannesburg RSA, Milan Italy, Chengdu China and Tokyo Japan.

For further information on EuroPCR, PCR London Valves, PCR Peripheral, PCR-CIT China Chengdu Valves, GulfPCR-GIM, AsiaPCR, AfricaPCR, PCR Tokyo Valves, and all PCR activities, please contact: Célia Vilà:

For more information, please visit: and follow us on Twitter using the hashtag #EuroPCR


Related Aspirin Articles:

Benefit seen for ticagrelor alone, without aspirin, in patients with ACS
The research was presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
Study: An aspirin a day does not keep dementia at bay
Taking a low-dose aspirin once a day does not reduce the risk of thinking and memory problems caused by mild cognitive impairment or probable Alzheimer's disease, nor does it slow the rate of cognitive decline, according to a large study published in the March 25, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Aspirin's health benefits under scrutiny
Taking a baby aspirin every day to prevent a heart attack or stroke should no longer be recommended to patients who haven't already experienced one of these events.
Aspirin may no longer be effective as cardiovascular treatment
A new paper in Family Practice, published by Oxford University Press, found that the widespread use of statins and cancer screening technology may have altered the benefits of aspirin use.
Migraine headaches? Consider aspirin for treatment and prevention
Evidence from 13 randomized trials of the treatment of migraine in 4,222 patients and tens of thousands of patients in prevention of recurrent attacks supports the use of high dose aspirin from 900 to 1,300 milligrams to treat acute migraine as well as low dose daily aspirin from 81 to 325 milligrams to prevent recurrent attacks.
Aspirin use after biliary tract cancer diagnosis
Researchers in this observational study examined if aspirin use after a diagnosis of a biliary tract cancer, which includes gallbladder cancer, was associated with reduced risk of death among nearly 3,000 patients.
Aspirin may prevent air pollution harms
A new study is the first to report evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin may lessen the adverse effects of air pollution exposure on lung function.
Aspirin should not be recommended for healthy people over 70
Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in those at the highest risk of cardiovascular disease.
Frequent use of aspirin can lead to increased bleeding
A new study published today in the Journal of the American Medical Association (JAMA) has found that taking aspirin on a regular basis to prevent heart attacks and strokes, can lead to an increase risk of almost 50 percent in major bleeding episodes.
Analyzing aspirin use in patients without cardiovascular disease
This study analyzed combined results from 13 randomized clinical trials with more than 164,000 participants to assess aspirin use with the prevention of cardiovascular events and bleeding in people without cardiovascular disease.
More Aspirin News and Aspirin Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at